Clinical trial

A Study of Elpipodect (MK-8189) in Participants With Schizophrenia (MK-8189-014)

NCT05406440

Study summary

ClinicalTrials.gov

A Study of Elpipodect (MK-8189) in Participants With Schizophrenia (MK-8189-014)

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Elpipodect Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2022-07-12

PhasePHASE1

Conditions

Schizophreniaverified · MONDO: schizophrenia

Interventions

ElpipodectDRUG

PlaceboDRUG

Sponsors & collaborators

Merck Sharp & Dohme LLClead sponsor

Mapped research locations

GlendaleCalifornia, United States1 Garden GroveCalifornia, United States1 MarltonNew Jersey, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05406440 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.